Therefore, we attempted to characterize biological and molecular hallmarks of newly established PTX-resistant GC cells and with bioinformatic screening, we also evaluated whether targeting the PI3K/Akt/mTOR or MAPK pathways exerted antitumor actions against PTX-resistant GC. The gene discussed is MTOR; the disease is gastric cancer.